Share
09:00 24 Feb 2017
The firm said the results showed patients given TroVax and low dose cyclophosphamide demonstrated “significant anti-5T4 immune responses”
Cancer cell
Oxford Biomedica noted that this was the first randomised study to show a benefit of immunotherapy in advanced colorectal cancer patients
Gene and cell therapy group Oxford Biomedica PLC (LON:OXB) got a boost today from “encouraging” results from a Phase I/II clinical trial involving its MVA-5T4 immunotherapy product, TroVax for patients with advanced colorectal cancer.
The biotech firm said a presentation by clinical investigators, given in a poster session at the American Society of Clinical Oncology and Society for Imumunotherapy of Cancer Clinical Immuno-Oncology Symposium in Orlando, Florida on February 23, showed that patients given TroVax and low dose cyclophosphamide (CPM) demonstrated “significant anti-5T4 immune responses” by treatment day 43.
The group added that secondary analysis revealed that both CPM and TroVax independently induced “highly beneficial anti-tumour immune responses, resulting in significant survival of end stage colorectal cancer patients, without any major toxicity.”
Oxford Biomedica noted that this was the first randomised study to show a benefit of immunotherapy in advanced colorectal cancer patients.
Commenting on the trial results, John Dawson, Oxford Biomedica’s chief executive officer said: "The presentation by the Clinical Investigators of the Phase I/II TaCTiCC study at the ASCO-SITC Clinical Immuno-Oncology symposium showed the potential benefit that Oxford BioMedica's immunotherapy (TroVax®) treatment could give to patients with advanced colorectal cancer."
Good luck and GOD bless,
George
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM